Science on the job: Teachers learn from tech firms
By EMERY P. DALESIO - AP - Sat Jul 26, 9:36AM CDT
RALEIGH, N.C. (AP) — A small but growing number of science and math teachers aren't spending the summer at the beach or catching up on books, they're toiling at companies, practicing the principles they teach.
Rockwood Repays Sachtleben Debts - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 27, 1:20PM CDT
Rockwood has repaid all outstanding borrowings under the secured facility of its fully-owned unit Sachtleben.
American Vanguard Tops in 4Q - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 07, 8:40AM CST
American Vanguard's fourth-quarter revenues and earnings were ahead of the Zacks Consensus Estimates.
Chemtura Misses Squarely - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 01, 8:50AM CST
Chemtura's fourth-quarter revenues and earnings missed the Zacks Consensus Estimates.
Rockwood Hikes Dividend - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 26, 6:55PM CST
Rockwood has increased its quarterly dividend by 15%.
Valspar Reaffirmed at Neutral - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 20, 3:40PM CST
We have retained our Neutral recommendation on paint and coatings maker Valspar Corporation.
Rockwood to Control Sachtleben - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 19, 7:10PM CST
Rockwood is acquiring full ownership of Sachtleben.
Sigma-Aldrich Hikes Dividend - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 19, 5:56PM CST
Sigma-Aldrich has increased its quarterly dividend by 7.5%.
Sigma-Aldrich Inks Deal with Olink - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 14, 6:20PM CST
Sigma-Aldrich has partnered with Olink Bioscience to distribute Duolink In Situ products worldwide.
ImmunoGen Progresses with IMGN901 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 14, 5:45PM CST
ImmunoGen Inc announced that it has finished enrolling patients for the initial stage of the two-stage NORTH phase II trial
Sigma-Aldrich Retained at Neutral - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 13, 3:00PM CST
We have maintained our Neutral recommendation on Sigma-Aldrich.